| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
eXoZymes Inc. Common Stock$7.7
-0.48 (-5.87%)
Market Cap
99.20 M
EPS
-1.09
P/E Ratio
-10.71 $
Value Trade
18.42 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.12 M
Operating CF
-1.52 M
Total Assets
4.02 M
Total Liabilities
2.49 M
Equity
1.53 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
1.44 M
Monthly Burn
508.00 K
Runway
1.7 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
3.89 K
52 Week Range
7.08 - 18.40
% held by Insiders
73.33 %
% held by Institutions
0.74 %
Enterprise Value
97.41 M
Total Shares
8.48 M
Short %
0.6 %
Float Shares
2.52 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EXOZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
eXoZymes Inc. Common Stock (EXOZ) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
EXOZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EXOZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EXOZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
EXOZ Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
EXOZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-EXOZ
Jun 17, 2026eXoZymes Inc. Announces Closing of $6 Million Public Offering Los Angeles, CA
eXoZymes Inc. has successfully closed a $6 million public offering, which includes the sale of common stock and warrants. The gross proceeds are intended to support the development of the company's AI-enhanced enzyme technology and related commercialization activities. Despite the positive implications for funding, the press release includes caution regarding potential risks to future performance and the lack of liquidity for the warrants sold. The company aims to pave the way for advancements in sustainable biomanufacturing.
Read more →-EXOZ
Jun 8, 2026eXoZymes, Inc. Announces Pricing of Public Offering of Common Stock and Warrants Los Angeles, CA
eXoZymes Inc. has announced the pricing of its public offering of units, consisting of shares of common stock and warrants, expected to raise around $5.33 million. The offering is set to close on June 9, 2026, pending customary closing conditions. The company plans to utilize the net proceeds for advancing its N-trans-caffeoyltyramine opportunities, as well as research and development, working capital, and capital expenditures. However, potential investors should be aware of the associated risks, including the lack of a trading market for the warrants and the conditions under which the warrants may reset.
Read more →-EXOZ
Mar 26, 2026eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
eXoZymes Inc. will host a webinar on March 31, 2026, to discuss its fourth quarter and full year 2025 results. CEO Michael Heltzen will lead the call, which will cover recent developments and future milestones. A press release detailing the results will be issued prior to the call, and investors can pre-register for the event.
Read more →-EXOZ
Jan 29, 2026eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot run N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in e
eXoZymes Inc. has reported successful results from its first 100-liter pilot production run of N-trans-caffeoyltyramine (NCT), achieving high performance metrics including a 99% reaction conversion rate and 90% yield. The use of AI-enhanced enzymes allowed for a scalable and robust biomanufacturing process, contradicting conventional scaling challenges typically seen in biological systems. This pilot marks a significant step towards commercializing a sustainable supply chain for NCT, as the company prepares to engage partners in formulation development and application testing. eXoZymes aims to refine their manufacturing techniques and expand production capabilities in 2026.
Read more →-EXOZ
Dec 11, 2025eXoZymes achieves 100 scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion. Los Angeles, CA
eXoZymes Inc. has announced a significant milestone by achieving a 100-fold scale-up in producing N-trans-caffeoyltyramine (NCT) through its advanced exozyme-based platform. This process boasts an exceptional conversion efficiency exceeding 99% from feedstock to product, paving the way for future biomanufacturing innovations. The achievement underscores the potential of cell-free enzyme systems to operate reliably at scale, overcoming challenges associated with traditional manufacturing methods. Further technical details and insights from the production process are expected in early 2026.
Read more →-EXOZ
Jun 26, 2025eXoZymes selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturing Monrovia, CA
eXoZymes Inc. has been selected as a core industry partner in the $9M NSF-funded Meta-PURE initiative aimed at advancing modular cell-free biomanufacturing. The project is led by Georgia Tech and will develop standardized, interoperable modules for diverse applications in synthetic biology. eXoZymes will contribute a cell-free ATP-generating module and a production module for the fragrance compound santalene. The initiative aims to enhance the scalability and accessibility of biomanufacturing technologies over a three-year period.
Read more →-EXOZ
Apr 2, 2025eXoZymes Provides Fourth Quarter and Full Year 2024 Update Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA
eXoZymes Inc. has provided an operational update for the fourth quarter and full year of 2024, emphasizing its focus on commercialization through partnerships and innovative AI-engineered enzymes. The company successfully completed its IPO and began trading on Nasdaq in late 2024, despite the challenging fundraising environment. CEO Heltzen highlighted ongoing initiatives to enhance the biomanufacturing process and the importance of achieving commercial applications.
Read more →-EXOZ
Apr 2, 2025eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully
eXoZymes Inc. announced the appointment of Damien Perriman as the new Chief Commercial Officer (CCO) to support its growth in biomanufacturing. With over two decades of experience in commercializing biotechnologies across multiple sectors, Perriman aims to enhance the company's efforts in scaling and commercializing biosolutions. This strategic hire is part of eXoZymes' commitment to pioneering sustainable alternatives in the chemical production industry through its AI-engineered enzymes.
Read more →-EXOZ
Nov 12, 2024Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering Shares to Begin Trading on NASDAQ on
Invizyne Technologies, Inc. has announced the pricing of its initial public offering (IPO), issuing 1,875,000 shares at $8.00 each, aiming to raise a total of $15 million. The shares are set to begin trading on the NASDAQ under the ticker symbol 'IZTC' on November 12, 2024, with an expected closing date on November 13, 2024. The funds will support expansion in production capabilities, business development, and working capital needs. This marks a significant milestone for the company as it prepares to commercialize its innovative enzymatic biomanufacturing platform.
Read more →Competitive Position
How EXOZ ranks across every disease it competes inCompetitive Position is a premium feature
See how EXOZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial